Skip to main navigation Skip to search Skip to main content

Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study

  • Guillermo Orti*
  • , Christophe Peczynski
  • , William Boreland
  • , Maeve O'Reilly
  • , Malte von Bonin
  • , Adriana Balduzzi
  • , Caroline Besley
  • , Krzysztof Kalwak
  • , Samppa Ryhaenen
  • , Tayfun Guengoer
  • , Robert F. Wynn
  • , Peter Bader
  • , Stephan Mielke
  • , Didier Blaise
  • , Persis Amrolia
  • , Ibrahim Yakoub-Agha
  • , Friso Calkoen
  • , Maria-Luisa Schubert
  • , Victoria Potter
  • , Herbert Pichler
  • Nicolaus Kroeger, Mi Kwon, Henrik Sengeloev, Anna Torrent, Yves Chalandon, Gwendolyn van Gorkom, Christian Koenecke, Charlotte Graham, Helene Schoemans, Ivan Moiseev, Olaf Penack, Zinaida Peric
*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

In patients diagnosed with B-acute lymphoblastic leukemia (B-ALL) or B-non-Hodgkin's lymphoma (B-NHL) relapsing after allogeneic stem cell transplantation (allo-HCT), it is a standard practice to perform anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. When collected from the patient after allo-HCT, the produced CAR-T cells are likely to be donor T-cell-derived, creating unknown safety risks due to their potential allo-reactivity. We therefore performed an EBMT registry-based study on the incidence of graft-versus-host disease (GvHD) in this setting. We included 257 allo-HCT patients (n = 172 >= 18 years) with B-ALL or B-NHL, treated with anti-CD19 CAR T-cells (tisagenlecleucel n = 184, brexucabtagene autoleucel n = 43 and axicabtagene ciloleucel n = 30), between 2018 and 2022. Three patients developed aGvHD, whereas 6 patients developed cGvHD after CAR T-cell. The 100-day cumulative incidence (CI) of new aGvHD was 1.6% and the 12-month CI of new cGvHD was 2.8%. The 1-year GvHD relapse-free survival and non-relapse mortality were 52.1% and 4.7%, respectively. Last, with a median follow up of 18.8 months, the 1-year overall survival was 76.8%. In summary, the GvHD rate in allo-HCT patients treated with CAR T-cell therapy is relatively low. Our data support the view that GvHD is not a major safety issue in this setting.
Original languageEnglish
Article number2227
Pages (from-to)431-437
Number of pages7
JournalLeukemia
Volume39
Issue number2
Early online date1 Nov 2024
DOIs
Publication statusPublished - Feb 2025

Keywords

  • CONSENSUS DEVELOPMENT PROJECT
  • ADULT B-CELL
  • CLINICAL-TRIALS
  • MALIGNANCY
  • PREVENTION
  • CRITERIA
  • RELAPSE
  • GVHD

Fingerprint

Dive into the research topics of 'Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study'. Together they form a unique fingerprint.

Cite this